In compliance with Regulation 7(3) of the SEBI (LODR), 2015, we hereby submit the compliance certificate for the year ended on 31st March, 2025 certifying that all activities in relation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Ltd has filed a compliance certificate under SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulation 7(3) for the financial year ended 31 March 2025. The certificate, jointly signed by the Company's Secretary and the authorised representative of its Registrar and Share Transfer Agent (RTA) — M/s Purva Sharegistry (India) Private Limited (SEBI Reg. No. INR000001112) — confirms that the RTA has properly handled all share transfer activities, both physical and electronic, on behalf of the company. The company's registered office is in Rajkot, Gujarat, and it is listed on BSE under Scrip Code 540359 with ISIN INE240T01014.
This is a routine, mandatory annual compliance filing and has no material impact on the company's operations, financials, or stock price. It simply reassures investors that share transfer and registry functions are being managed properly by a SEBI-registered RTA.